Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Payables (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Payables for 6 consecutive years, with $698000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Payables fell 77.31% year-over-year to $698000.0, compared with a TTM value of $698000.0 through Sep 2025, down 77.31%, and an annual FY2024 reading of $2.5 million, up 54.53% over the prior year.
  • Payables was $698000.0 for Q3 2025 at Barinthus Biotherapeutics, down from $1.8 million in the prior quarter.
  • Across five years, Payables topped out at $5.1 million in Q3 2023 and bottomed at $698000.0 in Q3 2025.
  • Average Payables over 5 years is $2.9 million, with a median of $2.5 million recorded in 2024.
  • The sharpest move saw Payables surged 113.4% in 2023, then plummeted 77.31% in 2025.
  • Year by year, Payables stood at $2.4 million in 2021, then surged by 54.94% to $3.7 million in 2022, then tumbled by 57.28% to $1.6 million in 2023, then soared by 54.53% to $2.5 million in 2024, then crashed by 71.79% to $698000.0 in 2025.
  • Business Quant data shows Payables for BRNS at $698000.0 in Q3 2025, $1.8 million in Q2 2025, and $1.4 million in Q1 2025.